- The key vendors in the global PTSD therapeutics market 2015-2019 are GlaxoSmithKline plc, Pfizer Inc. and Otsuka Pharmaceutical Co. Ltd.
London, 18 June 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the global PTSD therapeutics market 2015-2019. Growing public awareness is one of the major trends being witnessed in this market. The US Senate designated June 27 as National PTSD Awareness Day, and the National Center for PTSD designated June as PTSD Awareness Month in order to spread awareness about the disorder. The global PTSD therapeutics market is expected to post a CAGR of 1.09% during the forecast period of 2014-2019.
The market has huge growth opportunities for vendors because of the growing population of individuals with PTSD. Many companies are investing in the R&D of drugs for PTSD. For instance, Otsuka Pharmaceuticals and Lundbeck are engaged in the investigation of Brexpiprazole for the treatment of PTSD.
“Physicians often misdiagnose PTSD as depression and other anxiety disorders, leading to the prescription of drugs intended for these conditions,” says Faisal Ghaus, Vice President of Technavio Research.
“Many antidepressant drugs are commonly being prescribed for relieving symptoms of PTSD, including SSRIs, MAO inhibitors, tricyclic antidepressants, benzodiazepines, beta-blockers, anticonvulsants, atypical antipsychotics, and alpha-1 and alpha-2 adrenergic agonists.”
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
